O-nitro compounds, pharmaceutical compositions thereof and uses thereof

Abstract

The present invention provides O-nitro compound, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

1 . A method for treating or preventing cancer in a patient comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a O-nitro compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.  
     
     
         2 . The method of  claim 1  in which the cancer is breast cancer, renal cancer, brain cancer, colon cancer, colorectal cancer, prostrate cancer, lung cancer, any other solid tumor or lymphohematopoietic malignancy.  
     
     
         3 . The method of  claim 1  in which the O-nitro compound has the structure R 1 —O—NO 2  where R 1  is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, fused cycloalkyl, substituted fused cycloalkyl, substituted cycloalkyl, fused cycloalkylcycloheteroalkyl, substituted fused cycloalkylcycloheteroalkyl, cubyl, substituted cubyl, adamantyl or substituted adamantyl.  
     
     
         4 . The compound of  claim 3  in which R 1 —O—NO 2  has the structure:  
       
         
           
           
               
               
           
         
       
       wherein R 2 , R 3 , R 4 , R 5  and R 6  are independently hydrogen, alkyl or substituted alkyl.  
     
     
         5 . The compound of  claim 3  in which R 1 —O—NO 2  has the structure:  
       
         
           
           
               
               
           
         
       
     
     
         6 . The compound of  claim 3  in which R 1 —O—NO 2  has the structure:  
       
         
           
           
               
               
           
         
       
     
     
         7 . The compound of  claim 3  in which R 1 —O—NO 2  has the structure:  
       
         
           
           
               
               
           
         
         wherein X is —S—, —O—, —N(R 7 ), —P(O)OR 7 , or —BR 7  where R 7  is hydrogen or alkyl.  
       
     
     
         8 . The compound of  claim 3  in which R 1 —O—NO 2  has the structure:  
       
         
           
           
               
               
           
         
         wherein X is —S—, —O—, —N(R 7 ), —P(O)OR 7 , or —BR 7  where R 7  is hydrogen or alkyl.  
       
     
     
         9 . The compound of  claim 3  in which R 1 —O—NO 2  has the structure:  
       
         
           
           
               
               
           
         
       
     
     
         10 . The compound of  claim 3  in which R 1 —O—NO 2  has the structure:  
       
         
           
           
               
               
           
         
       
     
     
         11 . The compound of  claim 3  in which R 1 —O—NO 2  has the structure:  
       
         
           
           
               
               
           
         
       
     
     
         12 . The compound of  claim 3  in which R 1 —O—NO 2  has the structure:  
       
         
           
           
               
               
           
         
       
       wherein X is —S—, —O— or —N(R 7 ) where R 7  is hydrogen or alkyl.  
     
     
         13 . A pharmaceutical composition comprising an O-nitro compound or a pharmaceutically acceptable salt, hydrate or solvate thereof and a pharmaceutically acceptable vehicle.  
     
     
         14 . A method for treating tumor cells with a reduced intracellular environment in a patient, comprising administering to the patient in need of treatment a therapeutically effective amount of an O-nitro compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.  
     
     
         15 . A method for treating or preventing solid tumors in a patient, comprising administering to the patient in need of treatment or prevention a therapeutically effective amount of an O-nitro compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.  
     
     
         16 . A method for treating or preventing inflammation in a patient, comprising administering to the patient in need of treatment or prevention a therapeutically effective amount an O-nitro compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.  
     
     
         17 . A method for treating or preventing autoimmune disease in a patient, comprising administering to the patient in need of treatment or prevention a therapeutically effective amount of an O-nitro compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.  
     
     
         18 . A method for treating or preventing cardiovascular disease in a patient, comprising administering to the patient in need of treatment or prevention a therapeutically effective amount an O-nitro compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.